Skip to content
To the full analysis

Pharming Group stock: balance sheet and debt

PHARM.AS
$1.29Closing price of 12 Nov 2026MEQIRI Score 49 out of 100

Pharming Group has a debt to equity ratio of 0.42 and an interest coverage of 2x.

Daily figure as of 13 Nov 2026

Debt / Equity
0.42
Interest coverage
2x
Current ratio
2.59
Cash & equivalents
$179.88M
Total assets
$500.02M
Equity ratio
55.4%
Goodwill
$3.32M
Plus intangible assets of $132.22M
Net debt
−$64.09M
More cash than debt

Total assets and equity ratio

How large the balance sheet of Pharming Group N.V. is, how much of it is equity and how much is goodwill from acquisitions.

Equity ratio

Figures as a table
YearTotal assetsGoodwill and intangible assetsof which goodwillEquity ratioNet debt
2006$104.37M$38.24M$12.13M63.0%−$32.34M
2007$166.72M$41.07M$13.4M30.3%−$51.37M
2008$93.4M$34.87M$9.74M18.7%$20.06M
2009$80.07M$31.37M$6.18M23.8%$19.15M
2010$49.59M$1.55Mnot split out27.1%−$13.47M
2011$32.01M$987Knot split out−4.8%−$445.86K
2012$22.28M$707.54Knot split out−45.4%−$3.2M
2013$31.41M$559.25Knot split out16.0%−$21.46M
2014$67.75M$944.84Knot split out44.0%−$39.63M
2015$63.06M$791.55Knot split out37.8%−$18.73M
2016$126.78M$59.61Mnot split out21.7%$35.5M
2017$166.19M$67.94Mnot split out9.7%$23.56M
2018$214.48M$59.98Mnot split out28.8%$3.11M
2019$228.02M$79.32Mnot split out45.9%−$14.39M
2020$342.55M$94.23Mnot split out43.6%−$35.36M
2021$397.42M$95.04Mnot split out48.4%−$30.16M
2022$425.8M$75.12Mnot split out48.1%−$40.89M
2023$462.85M$71.27Mnot split out47.3%−$41.88M
2024$400.61M$61.04Mnot split out55.4%−$55.55M
2025$500.02M$135.54M$3.32M55.4%−$64.09M

The equity ratio divides total equity, including non-controlling interests, by total assets. Net debt is debt minus cash and short-term investments; a negative figure means cash exceeds debt. In years without separate goodwill, the table shows the sum of goodwill and intangible assets, because the data do not list goodwill separately there.

Equity and debt

What the company owns and owes

  • Cash & equivalents
  • Equity
  • Debt
Figures as a table
YearCash & equivalentsEquityDebtDebt / Equity
2006$34.42M$65.78M$2.08M0.03
2007$74.29M$50.58M$22.92M0.45
2008$32.52M$17.45M$52.57M3.01
2009$22.81M$19.07M$41.96M2.2
2010$13.7M$14.45M$236K0.02
2011$4.9M−$1.54M$4.45M−2.89
2012$6.97M−$7.65M$3.78M−0.37
2013$23.43M$5.01M$1.97M0.39
2014$41.57M$29.84M$1.93M0.06
2015$34.6M$23.84M$15.87M0.67
2016$31.89M$27.47M$67.39M2.45
2017$58.66M$16.11M$82.21M5.1
2018$80.31M$61.75M$83.42M1.35
2019$66.24M$104.59M$51.86M0.5
2020$167.94M$149.38M$132.58M0.89
2021$191.92M$192.92M$161.76M0.84
2022$208.58M$204.64M$167.69M0.82
2023$213.42M$218.78M$171.55M0.78
2024$167.82M$221.76M$112.26M0.51
2025$179.88M$277.1M$115.79M0.42

Data status and sources

Score
Daily value of 13 Nov 2026, recalculated nightly
Price
Closing price of 12 Nov 2026
Latest annual report
Fiscal year 2025, period end 31 Dec 2025
Currency
Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
Source
Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.

Mandatory disclosures for this rating

  • ; time horizon around 12 months
  • Rated Weak, published since 7 Nov 2026 (in the score history since 4 Nov 2026)
  • Valuation signal Overvalued since 10 Nov 2026, previously Fairly valued
  • End-of-day prices, metrics cached for up to 24 hours
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.

MEQIRI counts visits without cookies. With your consent we remember for 90 days where you came from, also in your account, count page changes and time on page, recognise your next visit and load the Meta Pixel, which measures our advertising. You can withdraw your consent at any time under Cookie settings. Privacy